Bionano Genomics (NASDAQ:BNGO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Bionano Genomics (NASDAQ:BNGO) to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings raised Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Bionano Genomics presently has an average rating of “Hold” and a consensus target price of $6.00.

Bionano Genomics Stock Performance

BNGO opened at $1.68 on Friday. The company’s 50 day moving average is $1.28 and its 200 day moving average is $1.22. The company has a current ratio of 2.48, a quick ratio of 1.96 and a debt-to-equity ratio of 0.11. The company has a market cap of $19.79 million, a price-to-earnings ratio of -0.56 and a beta of 1.65. Bionano Genomics has a 12-month low of $1.00 and a 12-month high of $2.23.

Bionano Genomics (NASDAQ:BNGO) last announced its earnings results on Monday, August 10th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.03. Bionano Genomics had a negative net margin of 106.58% and a negative return on equity of 78.78%. The business had revenue of ($6.67) million during the quarter, compared to analysts’ expectations of $7.55 million. On average, equities research analysts predict that Bionano Genomics will post -2.49 EPS for the current year.

Hedge Funds Weigh In On Bionano Genomics

An institutional investor recently bought a new stake in Bionano Genomics stock. GSA Capital Partners LLP purchased a new position in Bionano Genomics, Inc. (NASDAQ:BNGO) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 150,284 shares of the company’s stock, valued at approximately $170,000. GSA Capital Partners LLP owned 1.31% of Bionano Genomics at the end of the most recent reporting period. Institutional investors and hedge funds own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc is a life sciences company that develops genomic analysis technologies designed to identify structural variation and other genetic abnormalities that may be difficult to detect with conventional sequencing methods. The company’s platform is used in research, clinical, and pharmaceutical applications, including studies of cancer, inherited disease, and genome biology.

Its primary product is the Saphyr system, an optical genome mapping platform that analyzes long, fluorescently labeled DNA molecules as they pass through nanochannel arrays.